IB-T101 / Inceptor Bio, Grit Biotechnology - LARVOL DELTA

A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of IB-T101, an OUTLAST™-conditioned CD70-targeted CAR-T cell therapy, in patients with clear cell renal cell carcinoma (SITC 2025) - P1 | "Correlative assessments will include pre-treatment biopsies to assess the level of CD70 expression in the tumor.Trial Registration NCT06819293Ethics Approval The study was approved by the Tongji Hospital Medical Ethics Committee, ID TJ-IRB202412051-1. Study participants gave informed consent before enrolling in the study."

CAR T-Cell Therapy • Clinical • IO biomarker • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Malignancies • Oncology • Solid Tumor • CD70

A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma. (ASCO 2025) - "Additional objectives of the study are to assess the anti-tumor activity and the pharmacokinetics of IB-T101. Correlative assessments will include pre-treatment biopsies to assess the level of CD70 expression in the tumor."

IO biomarker • P1 data • Clear Cell Renal Cell Carcinoma • Kidney Cancer • Oncology • Solid Tumor • CD70

A phase 1, first-in-human study of IB-T101, an OUTLAST™ CAR-T product for the treatment of CD70-positive clear cell renal carcinoma (AACR 2025) - "Additional objectives of the study are to assess the anti-tumor activity and the pharmacokinetics of IB-T101. Correlative assessments will include pre-treatment biopsies to assess the level of CD70 expression in the tumor."

IO biomarker • P1 data • Clear Cell Renal Cell Carcinoma • Kidney Cancer • Oncology • Solid Tumor • CD70

Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing (PRNewswire) - "Inceptor Bio...announced that the first patient has been dosed in the clinical trial of IB-T101, the company's lead program. The trial marks a significant milestone for Inceptor Bio's efforts to address the unmet medical needs of patients with clear cell Renal Cell Carcinoma (ccRCC)....This Investigator-Initiated Trial (IIT) aims to evaluate the safety, tolerability, and preliminary efficacy of IB-T101 in patients with ccRCC who have relapsed on prior VEGF-targeting therapies alone or in combination with an immune checkpoint inhibitor. The trial will enroll patients across a dose-escalation phase to determine the optimal dose of IB-T101....In conjunction with this milestone, Inceptor Bio has successfully closed a $21 million Series A2 financing, which will support the ongoing clinical development of IB-T101 and the expansion of its next-generation cell therapy pipeline. The round was led by a syndicate of insiders including Kineticos Life Sciences."

Financing • Trial status • Clear Cell Renal Cell Carcinoma

IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Grit Biotechnology

New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor